Skip to main content

Advertisement

Log in

Risk factors associated with Clostridium difficile infection in adult oncology patients

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Clostridium difficile infection (CDI) prevention is particularly important for cancer patients, because diarrhea often results in dose reductions or delays of chemotherapy or radiotherapy. We conducted this study to better ascertain the incidence, susceptibility, and risk factors for CDI in cancer patients receiving chemotherapy at our hospital.

Methods

We performed a retrospective study among adult cancer patients admitted at “12 de Octubre” University Hospital between January 2009 through April 2013 who were diagnosed with diarrhea. Inpatient data were available on hospital medical records. We screened by immunochromatography system detecting glutamate dehydrogenase antigen, and C. difficile toxins A and B. Later, a polymerase chain reaction for detecting toxin B gene was performed.

Results

A total of 225 patients were included in the study, and 39 of them (17.3 %) were diagnosed with CDI. Type of tumor significantly differed between CDI patients, thus relative risk in each type of cancer was calculated after adjusting for age, antibiotic exposure, corticosteroid, and proton-pump inhibitor use. Patients with gastrointestinal tumors were less prone to CDI. Conversely, breast cancer patients have a greater predisposition to CDI. Antibiotic treatment was found to be associated with an increasing risk for CDI in breast cancer patients. Curiously, exposure to proton-pump inhibitors appeared protective in our cohort, except for lung cancer patients. However, we have not been able to find an association between a particular type of chemotherapy and CDI.

Conclusions

We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients. Our findings indicate a probable association between antibiotic use and CDI incidence, at least in certain cancer, such as breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L et al (2013) Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369:1195–1205. doi:10.1056/NEJMoa1216064

    Article  CAS  PubMed  Google Scholar 

  2. Khan A, Raza S, Batul SA, Khan M, Aksoy T, Baig MA, Berger BJ (2012) The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov 7:157–170

    Article  CAS  PubMed  Google Scholar 

  3. Lipp MJ, Nero DC, Callahan MA (2012) Impact of hospital-acquired Clostridium difficile. J Gastroenterol Hepatol 27:1733–1737. doi:10.1111/j.1440-1746.2012.07242.x

    Article  PubMed  Google Scholar 

  4. Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61:1–8. doi:10.1016/j.jinf.2010.03.025

    Article  CAS  PubMed  Google Scholar 

  5. Mezoff EA, Cohen MB (2013) Acid suppression and the risk of Clostridium difficile infection. J Pediatr 163:627–630. doi:10.1016/j.jpeds.2013.04.047

    Article  PubMed Central  PubMed  Google Scholar 

  6. Kim JS, Ward KK, Shah NR, Saenz CC, McHale MT, Plaxe SC (2013) Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics. Support Care Cancer 21:3103–3107. doi:10.1007/s00520-013-1888-2

    Article  PubMed  Google Scholar 

  7. Kelly CP, LaMont JT (2008) Clostridium difficile — more difficult than ever. N Engl J Med 359:1932–1940. doi:10.1056/NEJMra0707500

    Article  CAS  PubMed  Google Scholar 

  8. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S (2013) Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493–2499. doi:10.1200/JCO.2012.45.5899

    Article  CAS  PubMed  Google Scholar 

  9. Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, Kitzweger E, Ruckser R, Haslberger AG (2011) Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS One 6:e28654. doi:10.1371/journal.pone.0028654

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Morotomi N, Fukuda K, Nakano M, Ichihara S, Oono T, Yamazaki T, Kobayashi N, Suzuki T, Tanaka Y, Taniguchi H (2011) Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method. Biol Pharm Bull 34:1011–1020

    Article  CAS  PubMed  Google Scholar 

  11. Stringer AM, Gibson RJ, Bowen JM, Keefe DM (2009) Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 10:79–83

    Article  CAS  PubMed  Google Scholar 

  12. van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 6:e1000879. doi:10.1371/journal.ppat.1000879

    Article  PubMed Central  PubMed  Google Scholar 

  13. Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ (2010) Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 5:1–9

    Article  CAS  PubMed  Google Scholar 

  14. Bishop KD, Castillo JJ (2012) Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 53:1617–1619. doi:10.3109/10428194.2012.654472

    Article  PubMed  Google Scholar 

  15. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N et al (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693–1703. doi:10.1056/NEJMoa1012413

    Article  CAS  PubMed  Google Scholar 

  16. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084. doi:10.1016/S0140-6736(05)67420-X

    Article  CAS  PubMed  Google Scholar 

  17. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A (2014) Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306:G310–G319. doi:10.1152/ajpgi.00282.2013

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV (2012) Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10:225–233. doi:10.1016/j.cgh.2011.09.030

    Article  CAS  PubMed  Google Scholar 

  19. Nesher L, Rolston KV (2013) Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis 56:711–717. doi:10.1093/cid/cis998

    Article  PubMed  Google Scholar 

  20. Stewart DB, Yacoub E, Zhu J (2012) Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J Gastrointest Surg 16:1566–1572. doi:10.1007/s11605-011-1783-4

    Article  PubMed  Google Scholar 

  21. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B (2009) Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 30:253–264. doi:10.1111/j.1365-2036.2009.04037.x

    Article  CAS  PubMed  Google Scholar 

  22. Orellana-Miguel MA, Alcolea-Medina A, Barrado-Blanco L, Rodriguez-Otero J, Chaves-Sanchez F (2013) Algorithm proposal based on the C. Diff Quik Chek Complete ICT device for detecting Clostridium difficile infection. Enferm Infecc Microbiol Clin 31:97–99. doi:10.1016/j.eimc.2012.01.003

    Article  PubMed  Google Scholar 

  23. Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63. doi:10.1177/1758834009355164

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Hautmann MG, Hipp M, Kolbl O (2011) Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 6:89. doi:10.1186/1748-717X-6-89

    Article  PubMed Central  PubMed  Google Scholar 

  25. Hwang KE, Hwang YR, Seol CH, Park C, Park SH, Yoon KH, Park DS, Lee MK, Jeong ET, Kim HR (2013) Clostridium difficile infection in lung cancer patients. Jpn J Infect Dis 66:379–382

    Article  PubMed  Google Scholar 

  26. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107:1011–1019. doi:10.1038/ajg.2012.108

    Article  CAS  PubMed  Google Scholar 

  27. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107:1001–1010. doi:10.1038/ajg.2012.179

    Article  CAS  PubMed  Google Scholar 

  28. Reimer C (2013) Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 27:443–454. doi:10.1016/j.bpg.2013.06.001

    Article  CAS  PubMed  Google Scholar 

  29. Heidelbaugh JJ, Metz DC, Yang YX (2012) Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 66:582–591. doi:10.1111/j.1742-1241.2012.02921.x

    Article  CAS  PubMed  Google Scholar 

  30. Chopra T, Alangaden GJ, Chandrasekar P (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 8:1113–1119. doi:10.1586/eri.10.95

    Article  PubMed  Google Scholar 

  31. Baier R, Morphis B, Marsella M, Mermel LA (2013) Clostridium difficile surveillance: a multicenter comparison of LabID events and use of standard definitions. Infect Control Hosp Epidemiol 34:653–655. doi:10.1086/670642

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest to disclose.

The authors have had full control of all primary data for the study, and they agree to allow the journal to review their data if requested.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Teresa Agulló-Ortuño.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodríguez Garzotto, A., Mérida García, A., Muñoz Unceta, N. et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 23, 1569–1577 (2015). https://doi.org/10.1007/s00520-014-2506-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2506-7

Keywords

Navigation